Insider Selling: Bioventus (NASDAQ:BVS) Director Sells 12,000 Shares of Stock

Bioventus Inc. (NASDAQ:BVS) Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bioventus Stock Up 0.2%

NASDAQ:BVS traded up $0.02 on Friday, hitting $8.62. 286,351 shares of the company’s stock were exchanged, compared to its average volume of 334,578. The firm has a 50-day moving average price of $8.25 and a 200-day moving average price of $7.54. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. Bioventus Inc. has a 52 week low of $5.81 and a 52 week high of $10.13. The company has a market cap of $716.75 million, a P/E ratio of 12.65 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $157.90 million during the quarter. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Institutional Investors Weigh In On Bioventus

Several hedge funds have recently bought and sold shares of BVS. Caitong International Asset Management Co. Ltd lifted its stake in Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares during the last quarter. PharVision Advisers LLC bought a new stake in Bioventus in the second quarter valued at approximately $67,000. Covestor Ltd raised its stake in Bioventus by 28.0% in the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after buying an additional 2,176 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Bioventus in the second quarter valued at approximately $72,000. Finally, HB Wealth Management LLC acquired a new stake in shares of Bioventus in the third quarter valued at approximately $72,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BVS shares. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Barrington Research upped their price objective on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Craig Hallum increased their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $14.25.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.